These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 17146471)

  • 21. A critique of the dopamine hypothesis of schizophrenia and psychosis.
    Moncrieff J
    Harv Rev Psychiatry; 2009; 17(3):214-25. PubMed ID: 19499420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does the dopamine hypothesis explain schizophrenia?
    Lau CI; Wang HC; Hsu JL; Liu ME
    Rev Neurosci; 2013; 24(4):389-400. PubMed ID: 23843581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of schizophrenia in the 21st Century: beyond the neurotransmitter hypothesis.
    Rogers DP; Goldsmith CA
    Expert Rev Neurother; 2009 Jan; 9(1):47-54. PubMed ID: 19102668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Status of the dopaminergic system in post-mortem brain in schizophrenia.
    Reynolds GP; Czudek C
    Psychopharmacol Bull; 1988; 24(3):345-7. PubMed ID: 3153492
    [No Abstract]   [Full Text] [Related]  

  • 25. The molecular and cellular neurobiology of nicotine abuse in schizophrenia.
    Mobascher A; Winterer G
    Pharmacopsychiatry; 2008 Sep; 41 Suppl 1():S51-9. PubMed ID: 18756421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Origins and perspectives of schizophrenia research.
    Faludi G; Dome P; Lazary J
    Neuropsychopharmacol Hung; 2011 Dec; 13(4):185-92. PubMed ID: 22184186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The muscarinic system, cognition and schizophrenia.
    Carruthers SP; Gurvich CT; Rossell SL
    Neurosci Biobehav Rev; 2015 Aug; 55():393-402. PubMed ID: 26003527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The possible involvement of metabotropic glutamate receptors in schizophrenia.
    Krivoy A; Fischel T; Weizman A
    Eur Neuropsychopharmacol; 2008 Jun; 18(6):395-405. PubMed ID: 18063347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia.
    Hattori S; Murotani T; Matsuzaki S; Ishizuka T; Kumamoto N; Takeda M; Tohyama M; Yamatodani A; Kunugi H; Hashimoto R
    Biochem Biophys Res Commun; 2008 Aug; 373(2):298-302. PubMed ID: 18555792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
    Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
    Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interactive memory systems and category learning in schizophrenia.
    Kéri S
    Neurosci Biobehav Rev; 2008; 32(2):206-18. PubMed ID: 17854895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The kynurenic acid hypothesis of schizophrenia.
    Erhardt S; Schwieler L; Nilsson L; Linderholm K; Engberg G
    Physiol Behav; 2007 Sep; 92(1-2):203-9. PubMed ID: 17573079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Biochemical aspects of schizophrenia].
    Sano A; Kakimoto Y
    Tanpakushitsu Kakusan Koso; 1990 May; 35(7 Suppl):1380-7. PubMed ID: 1972588
    [No Abstract]   [Full Text] [Related]  

  • 34. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development.
    Marek GJ
    Int Rev Neurobiol; 2007; 78():165-92. PubMed ID: 17349861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of muscarinic receptors in the pathology of schizophrenia.
    Dean B
    Am J Med Genet B Neuropsychiatr Genet; 2004 Apr; 126B(1):8-9. PubMed ID: 15048640
    [No Abstract]   [Full Text] [Related]  

  • 36. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Schizophrenia: moving beyond monoamine antagonists.
    Conn PJ; Tamminga C; Schoepp DD; Lindsley C
    Mol Interv; 2008 Apr; 8(2):99-107. PubMed ID: 18403654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computational models of schizophrenia and dopamine modulation in the prefrontal cortex.
    Rolls ET; Loh M; Deco G; Winterer G
    Nat Rev Neurosci; 2008 Sep; 9(9):696-709. PubMed ID: 18714326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alterations of dopamine and serotonin transmission in schizophrenia.
    Remington G
    Prog Brain Res; 2008; 172():117-40. PubMed ID: 18772030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipsychotic drug actions on gene modulation and signaling mechanisms.
    Molteni R; Calabrese F; Racagni G; Fumagalli F; Riva MA
    Pharmacol Ther; 2009 Oct; 124(1):74-85. PubMed ID: 19540875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.